A Chicago Biomedical Consortium Hub of Innovative Technologies for Entrepreneurship and Science (CBC - HITES)

芝加哥生物医学联盟创业与科学创新技术中心 (CBC - HITES)

• 批准号: 10783500
• 负责人: SATISH N NADIG
• 金额: $ 99.99万
• 依托单位: NORTHWESTERN UNIVERSITY AT CHICAGO
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10783500
• 关键词: Active Learning; Address; Area; Award; Biological Products; Biological Sciences; Biotechnology; Businesses; Capital; Cell Therapy; Chicago; Cities; Clinical; Clinical Trials; Clinical and Translational Science Awards; Community Physician; Development; Discipline; Doctor of Philosophy; Ecosystem; Educational Curriculum; Engineering; Ensure; Entrepreneurship; Equity; Evaluation; Familiarity; Feedback; Funding; Funding Agency; Human Resources; Illinois; Industry; Infrastructure; Institution; Investments; Joints; Knowledge; Leadership; Link; Marketing; Medicine; Methods; Modality; Nanotechnology; Nature; Occupations; Pharmaceutical Preparations; Philanthropic Fund; Physicians; Process; Protein Engineering; Request for Applications; Research; Research Contracts; Research Personnel; Resources; Science; Scientist; Service delivery model; Services; Societies; Spottings; Supervision; Surgeon; Talents; Technology; Therapeutic; Time; Training; Translating; Translations; Triage; Universities; Validation; Work; clinical implementation; clinical translation; cohort; commercialization; experience; experimental study; gene therapy; health care service organization; implementation science; innovation; innovative technologies; interest; invention; manufacture; metropolitan; novel diagnostics; novel therapeutics; operation; programs; recruit; research clinical testing; science teacher; small molecule; synthetic biology

PROJECT SUMMARY With three R1 universities and multiple research institutions, the Chicago Metropolitan Statistical Area is awash with academic innovation but needs to attract more early-stage biopharma specific capital and more “bio- entrepreneurs” trained to link university-based projects to the know-how and funding that can launch a biomedical application into the emerging ecosystem. The Chicago Biomedical Consortium (CBC), a philanthropically funded research consortium between the University of Illinois Chicago (UIC), the University of Chicago (UC), and Northwestern University (NU) was founded in 2006, reimagined in 2016, and renewed in 2022 to bridge the Academic Innovator’s (AcIns) knowledge gap from idea to clinical implementation. Led by Northwestern University, anchored on CBC infrastructure that has developed diverse cohorts of PhD trained Entrepreneurial Fellows (EFs) and enabled translational awards across the three major Chicago universities, incorporating clinical translational expertise from a multi-campus network, and making such services available across nine Chicago research institutions, the Chicago Biomedical Consortium Hub for Innovative Technology and Entrepreneurship in the Sciences (CBC-HITES) will build a scaled multi-campus, academic service center for AcIns who want to develop biopharma small molecules, biologics, and new diagnostic/therapeutic modalities (e.g. cell and genetic therapies). The CBC-HITES will provide Chicago’s AcIns with multiple services, starting with the Request for Applications (RFA) stage and culminating in project execution. Under expert supervision by ex-industry personnel and a professional biopharmaceutical project manager, the center’s EFs will develop the AcIns’ ideas into industry grade analyses and project plans. Analyses are scientifically and clinically validated and, ultimately, validated by the end buyer, through an EF/AcIn joint presentation to a venture External Review Board (venture ERB) to inform funding. CBC – HITES’s leadership includes physician/surgeon scientists and expert drug hunters with connections to the city’s Clinical and Translational Science Awards (CTSA)s, community physician groups and healthcare organizations to better integrate clinical perspectives with deep discovery capabilities. The center also incorporates regulatory and implementation science into the hub. Projects funded by CBC-HITES will engage VC 1-2 years before equity financing is needed, and, depending on when they are screened out, unfunded projects receive a large body of research and a gap analysis that can be used for resubmission or alternative funding. VC are connected to promising AcIns and curated research, making their jobs easier. During their one to two years of training, EFs are networked to the universities, each other, and the broader ecosystem and then go to work in Chicago’s entrepreneurial ecosystem, pulling more academic assets out of the universities and thus maximizing the utility of their training. Intentionally recruiting diverse cohorts of EFs enables a strong, inclusive bioeconomy that can attract VC funding and more talent.

项目摘要 芝加哥大都会统计区拥有三所R1大学和多个研究机构， 学术创新，但需要吸引更多的早期生物制药专用资本和更多的“生物- 企业家”接受培训，将基于大学的项目与可以启动一个 生物医学应用到新兴的生态系统中。芝加哥生物医学联盟（CBC）， 由伊利诺伊大学芝加哥分校（UIC）、 芝加哥（UC）和西北大学（NU）成立于2006年，重新设想于2016年，并更新 在2022年，弥合学术创新者（AcIns）从想法到临床实施的知识差距。LED 西北大学，以CBC基础设施为基础，开发了不同的博士生群体。 企业家研究员（EF），并在三大芝加哥大学启用翻译奖， 整合来自多校区网络的临床翻译专业知识，并提供此类服务 在九个芝加哥研究机构中，芝加哥生物医学联盟创新中心 科学技术和创业（CBC-HITES）将建立一个规模化的多校区，学术 为想要开发生物制药小分子，生物制剂和新产品的AcIns服务中心 诊断/治疗方式（例如细胞和遗传疗法）。 CBC-HITES将为芝加哥的AcIns提供多种服务，从申请请求开始 (RFA)并在项目执行中达到高潮。在前行业人员的专家监督下， 作为一名专业的生物制药项目经理，该中心的EF将把AcIns的想法转化为产业 等级分析和项目计划。分析经过科学和临床验证，并最终通过 最终买方，通过EF/AcIn联合向风险外部审查委员会（风险ERB）提交报告， 知情供资。CBC - HITES的领导层包括医生/外科医生科学家和专家药物猎人， 与城市的临床和转化科学奖（CTSA），社区医生团体的联系 和医疗保健组织，以更好地将临床观点与深度发现能力相结合。中心 还将监管和实施科学纳入该中心。 CBC-HITES资助的项目将在需要股权融资前1-2年与VC合作， 当它们被筛选出来时，没有资金的项目会得到大量的研究和差距分析， 用于重新提交或替代供资。VC与有前途的AcIns和策划研究有关， 让他们的工作更轻松在一到两年的培训期间，EF与大学建立了网络， 其他的，更广泛的生态系统，然后去工作，在芝加哥的创业生态系统，拉更多的 这将使学术资产从大学中分离出来，从而最大限度地发挥其培训的效用。有意招募 多样化的创业基金群体能够实现强大的、包容性的生物经济，从而吸引风险投资和更多人才。